AKT1 and breast carcinoma: This observation aligns with extensive preclinical work demonstrating that response to capivasertib in breast cancer models is highly dependent upon levels of AKT activity [45, 46] and that phosphorylation of AKT cannot be fully predicted by genomic alterations of its regulators [6, 10, 18].